Profile data is unavailable for this security.
About the company
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
- Revenue in USD (TTM)19.24bn
- Net income in USD1.52bn
- Incorporated1906
- Employees75.00k
- LocationBecton Dickinson and CoOne Becton DriveFRANKLIN LAKES 07417-1880United StatesUSA
- Phone+1 (201) 847-6800
- Websitehttps://www.bd.com/
Mergers & acquisitions
| Acquired company | BDX:NYQ since announced | Transaction value |
|---|---|---|
| Parata Systems LLC | 0.75% | 1.53bn |
| Cytognos SL | -0.59% | -- |
| Scanwell Health Inc | 0.72% | -- |
| Tissuemed Ltd | 3.16% | -- |
| Venclose Inc | 5.20% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 12.33bn | 828.00m | 58.53bn | 41.00k | 71.03 | -- | 31.33 | 4.75 | 0.5763 | 0.5763 | 8.58 | -- | -- | -- | -- | 300,707.30 | -- | 3.26 | -- | 4.00 | 68.48 | 69.40 | 7.16 | 8.03 | -- | 6.27 | -- | 0.00 | 19.92 | 7.23 | 956.52 | 23.20 | 1.75 | -- |
| Edwards Lifesciences Corp | 5.36bn | 1.46bn | 65.79bn | 15.70k | 45.92 | 11.07 | 41.36 | 12.29 | 2.31 | 2.31 | 8.50 | 9.59 | 0.6658 | 1.59 | 8.39 | 341,082.80 | 18.09 | 15.99 | 20.45 | 18.95 | 77.78 | 75.11 | 27.18 | 23.63 | 2.60 | -- | 0.0911 | 0.00 | 19.29 | 12.04 | 82.55 | 21.42 | 8.69 | -- |
| Becton Dickinson and Co | 19.24bn | 1.52bn | 72.47bn | 75.00k | 48.04 | 2.84 | 19.26 | 3.77 | 5.29 | 5.79 | 66.91 | 89.39 | 0.3579 | 3.46 | 8.96 | 256,586.70 | 3.00 | 2.61 | 3.48 | 2.96 | 45.14 | 46.63 | 8.38 | 7.49 | 0.9017 | 5.36 | 0.391 | 72.79 | 18.29 | 10.16 | 161.02 | 15.45 | 11.39 | 4.69 |
| Stryker Corporation | 17.63bn | 2.08bn | 81.64bn | 46.00k | 39.69 | 5.21 | 26.79 | 4.63 | 5.44 | 5.44 | 46.09 | 41.43 | 0.5056 | 1.73 | 6.02 | 383,239.10 | 5.96 | 6.73 | 6.81 | 7.95 | 64.85 | 65.57 | 11.79 | 13.16 | 1.15 | -- | 0.4605 | 42.39 | 19.21 | 8.60 | 24.70 | 3.90 | 1.39 | 11.20 |
| Intuitive Surgical, Inc. | 5.96bn | 1.43bn | 85.82bn | 9.79k | 61.39 | 7.14 | 47.38 | 14.39 | 3.91 | 3.91 | 16.28 | 33.67 | 0.4587 | 2.94 | 7.75 | 608,986.00 | 11.18 | 14.12 | 12.25 | 15.68 | 68.16 | 68.83 | 24.36 | 29.38 | 4.74 | -- | 0.00 | 0.00 | 31.01 | 16.10 | 60.72 | 18.22 | 45.67 | -- |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2022 | 25.15m | 8.82% |
| The Vanguard Group, Inc.as of 31 Mar 2022 | 23.36m | 8.20% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 14.04m | 4.93% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 12.58m | 4.41% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 11.35m | 3.98% |
| Morgan Stanley Investment Management Ltd.as of 31 Mar 2022 | 6.68m | 2.34% |
| Parnassus Investments LLCas of 30 Jun 2022 | 5.45m | 1.91% |
| Geode Capital Management LLCas of 31 Mar 2022 | 4.61m | 1.62% |
| Generation Investment Management LLPas of 31 Mar 2022 | 4.50m | 1.58% |
| Massachusetts Financial Services Co.as of 31 Mar 2022 | 4.49m | 1.58% |
